U.S. Cancer Immunotherapy Market Size & Outlook, 2023-2030
U.S. cancer immunotherapy market, 2018-2030 (US$M)
Related Markets
U.S. cancer immunotherapy market highlights
- The U.S. cancer immunotherapy market generated a revenue of USD 52,343.0 million in 2023 and is expected to reach USD 84,612.6 million by 2030.
- The U.S. market is expected to grow at a CAGR of 7.1% from 2024 to 2030.
- In terms of segment, monoclonal antibodies was the largest revenue generating product in 2023.
- Oncolytic Viral Therapies and Cancer Vaccines is the most lucrative product segment registering the fastest growth during the forecast period.
Cancer immunotherapy market data book summary
| Market revenue in 2023 | USD 52,343.0 million |
| Market revenue in 2030 | USD 84,612.6 million |
| Growth rate | 7.1% (CAGR from 2023 to 2030) |
| Largest segment | Monoclonal antibodies |
| Fastest growing segment | Oncolytic Viral Therapies and Cancer Vaccines |
| Historical data | 2018 - 2022 |
| Base year | 2023 |
| Forecast period | 2024 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Monoclonal Antibodies, Check Point Inhibitors, Oncolytic Viral Therapies and Cancer Vaccines |
| Key market players worldwide | Pfizer Inc, AstraZeneca PLC, Merck & Co Inc, Roche Holding AG, Bristol-Myers Squibb Co, Novartis AG ADR, Eli Lilly and Co, Johnson & Johnson, Immunocore Holdings PLC ADR |
Other key industry trends
- In terms of revenue, U.S. accounted for 41.7% of the global cancer immunotherapy market in 2023.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2030.
- In North America, U.S. cancer immunotherapy market is projected to lead the regional market in terms of revenue in 2030.
- Canada is the fastest growing regional market in North America and is projected to reach USD 6,953.0 million by 2030.
Monoclonal antibodies was the largest segment with a revenue share of 67.06% in 2023. Horizon Databook has segmented the U.S. cancer immunotherapy market based on monoclonal antibodies, check point inhibitors, oncolytic viral therapies and cancer vaccines covering the revenue growth of each sub-segment from 2018 to 2030.
Cancer immunotherapy market in the U.S. is driven primarily by the high incidence of cancer, advancements in medical science, increased funding for R&D in oncology, high consumer awareness, and proactive government initiatives. Some of the latest market trends in cancer immunotherapy in the U.S., in 2019, were:
(i) Checkpoint immunotherapy raising the long-term survival bar: for instance, combination of CTLA-4 and PD-1 inhibitor has shown double response rate than PD-1 monotherapy in liver cancer.
(ii) Introduction of immunotherapy in the earlier stages of treatment can yield better results: for instance, PD-1 immunotherapy, in combination with chemotherapy, can double the survival rate when used as first-line.
(iii) Biomarkers and PD-L1 expression levels can predict and compare response rates to monotherapy and combination therapy.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Cancer Immunotherapy Market Scope
Cancer Immunotherapy Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|
U.S. cancer immunotherapy market size, by product, 2018-2030 (US$M)
U.S. Cancer Immunotherapy Market Outlook Share, 2023 & 2030 (US$M)
Related industry reports
Related regional statistics
No records
No related regions found.
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
